digital gene expression profiling

NanoString will initially draw $60 million at close, which will net it approximately $8 million after repaying its existing debt with the investment firm.

The company is marketing the panel, which runs on NanoString Technologies' nCounter System, to chemical and cosmetics firms as a replacement for animal models.

The partners will use NanoString's PanCancer panel in NCI-sponsored trials to characterize immune activity and develop potentially predictive gene signatures.

The five CROs will be able to offer DSP analyses to their customers through a technology access program ahead of NanoString's planned platform launch in 2019.

In blood samples from infected individuals, a seven-gene signature apparently distinguishes between bacterial and viral culprits, a distinction important to antibiotic use.

A five-gene signature was linked to both event-free survival and overall survival in individuals with a type of rhabdomyosarcoma missing a prognostically informative gene fusion.

The approach combines barcoding of individual mRNA molecules from single cells with next-generation sequencing.

DermTech announced this week that it has raised $5.6 million in a Series B financing round, which it will use to commercialize its melanoma detection test using Life Technologies' OpenArray quantitative real-time PCR system and to establish a CLIA-certified lab facility in which

Takeda will be the exclusive distributor in Japan for WaferGen's SmartChip System to researchers conducting gene expression studies.

The University of Nevada’s School of Medicine will use a March of Dimes grant to study gene expression in a variant that could be used to develop a screening test for preterm birth.

Pages

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.